■ Hanmi Pharmaceutical announced on the 14th that it will participate in the American Association for Cancer Research (AACR 2025) conference, held in Chicago, USA, from the 25th to the 30th of this month (local time), revealing 11 results from non-clinical studies, the most in the domestic industry. At this AACR, Hanmi Pharmaceutical will present a total of seven candidate substances, including two EHZ1/2 dual inhibitors (HM97662), two selective HER2 inhibitors (HM100714), one MAT2A inhibitor (HM100760), one SOS1 inhibitor (HM101207), a STING mRNA anticancer drug, two p53-mRNA anticancer drugs, and two BH3120 studies based on a dual antibody platform (PentumBody) that is being actively developed by Beijing Hanmi Pharmaceutical.
■ JW Pharmaceutical stated on the 14th that it confirmed the effect of LDL-cholesterol level improvement in patients who switched from a statin monotherapy to 'Rivarojet' for hyperlipidemia treatment. Rivarojet is a two-drug combination consisting of 'pitavastatin' and 'ezetimibe,' and it is the first improved new drug in South Korea combining pitavastatin and ezetimibe among statin formulations. A research team led by Professor Kim Sang-hyun from Boramae Medical Center is analyzing the efficacy and safety over 48 weeks for 7,197 hyperlipidemia patients post-switch to Rivarojet. The research team found that LDL-cholesterol levels decreased steadily at 8 weeks, 24 weeks, and 48 weeks after switching the treatment from six statin monotherapies, including atorvastatin and rosuvastatin, to Rivarojet among 2,221 clinically early registered patients.
■ Huons announced on the 14th that it sponsored the 2025 first half Type 1 Diabetes Workshop 'Our Bolus' organized by the Korean Type 1 Diabetes Association. The workshop aims to connect Type 1 diabetes patients and help them maintain a healthy lifestyle through mutual support and management. The event, held on the 12th at SpaceShare Gangnam Station in Seocho-gu, Seoul, was set up for adult Type 1 diabetes patients to communicate with each other and share the latest treatment information and health management methods. About 100 participants, including patients and families, shared information and experiences through various programs, including a lecture on 'Healthy Body, Healthy Mind' and group discussions.
■ Curocell announced on the 14th that it will present the results of non-clinical studies on its allogeneic CAR-T therapy targeting T-cell-derived blood cancer at the American Association for Cancer Research (AACR) held in Chicago, USA. The research results have garnered attention as they indicate new possibilities for treating rare, intractable blood cancers, overcoming the limitations of existing autologous CAR-T therapies. Curocell has been focusing on developing allogeneic CAR-T therapies using cells derived from healthy donors. According to an abstract released prior to the AACR presentation, Curocell confirmed a strong anticancer effect with its latest technology applied allogeneic CAR-T therapy 'CD5 gamma delta (Gammadelta, γδ) CAR-T.'
■ SD BIOSENSOR announced on the 14th that it will participate in the largest European Clinical Microbiology and Infectious Diseases Congress (ESCMID Global 2025) held in Vienna, Austria. SD BIOSENSOR will operate a large standalone booth and conduct a symposium on the 14th. The symposium will focus on 'solutions for enhancing accessibility in sexually transmitted infection diagnostics.' During the event, speakers will introduce an innovative point-of-care molecular diagnostic platform, STANDARD M10, that enables rapid and accurate detection of sexually transmitted infections, including chlamydia, gonorrhea, and human papillomavirus (HPV), and discuss ways to contribute to public health through early testing and improving diagnostic accessibility and tracking infection trends.
■ Onconic Therapeutics adjusted its revenue estimate for the year to 24.9 billion won, up approximately 54% from the previous estimate of 16.2 billion won, as announced on the 14th. The company explained that the upward revision is due to the domestic and international market expansion of its new drug, Zacuvo. The forecast for operating losses was revised from the previous 3.4 billion won to 5.4 billion won. The company secured surplus profits of 10.9 billion won by resolving deficits through a capital reserve compensation approved during last month's general shareholder meeting.
■ Coreline Soft announced on the 14th that it has signed a memorandum of understanding with the Chinese medical imaging information technology company 'Shuhai' to establish a strategic partnership for the expansion of its AI-based platform. Under the agreement, the two corporations will cooperate in enhancing AI technologies and joint research and development of new products. Kim Jin-guk, CEO of Coreline Soft, noted that 'China is the largest market in the world for the number of patients with pulmonary diseases, and the rapid spread of government-led medical AI adoption is happening,' adding that 'this partnership will strengthen our position in the Asian market.'
■ HANDOK officially launched the upgraded version of the continuous glucose monitoring device BarozenFit on the 14th. To mark the official launch of BarozenFit, HANDOK will run a 5+1 event for BarozenFit on its official online health store and Naver HANDOK Mall from April 14 to 20. BarozenFit allows users to check their blood sugar levels and trends conveniently and accurately, without needing to go through the calibration process required for fingertip blood sampling, and calibration can be done freely as needed. The initial stabilization time for blood glucose data display after sensor attachment has been shortened from 2 hours to 30 minutes, facilitating rapid monitoring. Existing products can continue to be used while updating the BarozenFit app for immediate application. The device can be used for up to 15 days, and its small, lightweight sensor weighing 4.5g features water-resistant capability, allowing for free activities while the sensor is attached to the arm.
■ i-SENS announced on the 14th that it will sell the smart blood glucose package 'My Health Phone' in collaboration with Samsung Electronics from the 14th to May 11. 'My Health Phone' is an integrated service model providing a healthcare-specialized package that includes the Galaxy S25 series smartphone equipped with the continuous glucose monitoring device 'CareSense Air' and the associated app, as well as the Galaxy Watch 7 and coaching services, utilizing the B2B dedicated Knox solution that supports auto-installation of apps. CareSense Air is the first commercially available continuous glucose monitoring device in South Korea, and unlike existing self-measuring blood glucose devices, it automatically measures blood glucose continuously with a wearable sensor attached to the user's arm. Users can monitor blood glucose data in real-time and track changes in blood glucose continuously through smartphones or smartwatches, significantly alleviating the daily burden for diabetes patients.
■ Dong-A Pharmaceutical announced on the 14th that the 'Mary Orchestra Han River Park Concert,' hosted by the Mary Foundation and sponsored by the company, was held on the 11th at the southern end of Banpo Bridge on Sebit Island. The concert was conducted in collaboration with the Mary Orchestra and the Meiji University Orchestra of Japan, featuring K-pop, animation, and movie original soundtracks (OST) for citizens to easily enjoy.
■ Merck Korea announced on the 14th that it will hold the 9th Merck BioForum Korea 2025. This forum will share insights on the latest trends in the pharmaceutical and biotech industry, innovations in AI and digital-based manufacturing processes, and future market changes, while also exploring the key role that Merck's bioprocessing production center, scheduled to open in 2026, will play in the pharmaceutical and biotech market in the Asia-Pacific region.